Psoriatic Arthritis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Psoriatic Arthritis - Pipeline Review, H2 2016

Psoriatic Arthritis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Psoriatic Arthritis - Pipeline Review, H2 2016
Published Nov 16, 2016
231 pages — Published Nov 16, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 9, 8, 10, 2, 15, 7 and 2 respectively.Psoriatic Arthritis.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
<

  
Source:
Document ID
GMDHC8680IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Psoriatic Arthritis Overview131
Therapeutics Development142
  Pipeline Products for Psoriatic Arthritis Overview141
  Pipeline Products for Psoriatic Arthritis Comparative Analysis151
Psoriatic Arthritis Therapeutics under Development by Companies163
Psoriatic Arthritis Pipeline Products Glance194
  Late Stage Products191
  Clinical Stage Products201
  Early Stage Products211
  Unknown Stage Products221
Psoriatic Arthritis Products under Development by Companies234
Psoriatic Arthritis Companies Involved in Therapeutics Development2733
  3SBio Inc.271
  AbbVie Inc281
  AbGenomics International, Inc.291
  Alteogen Inc.301
  Amgen Inc.311
  Biocon Limited321
  Bionovis SA331
  Bristol-Myers Squibb Company341
  Celgene Corporation351
  Coherus BioSciences, Inc.361
  Eli Lilly and Company371
  Forward Pharma A/S381
  Genor BioPharma Co Ltd391
  Innovent Biologics, Inc.401
  Johnson &Johnson411
  Kadmon Corporation, LLC421
  KPI Therapeutics, Inc.431
  Momenta Pharmaceuticals, Inc.441
  Morphotek, Inc.451
  Mycenax Biotech Inc.461
  NeuClone Pty Ltd471
  Novo Nordisk A/S481
  Oncobiologics, Inc.491
  Pfizer Inc.501
  Prothena Corporation Plc511
  Reliance Life Sciences Pvt. Ltd.521
  Sandoz International GmbH531
  Therapeutic Proteins International, LLC541
  UCB SA551
  Valeant Pharmaceuticals International, Inc.561
  Vitae Pharmaceuticals, Inc.571
  Vitaeris Inc581
  Xbrane Biopharma AB591
Psoriatic Arthritis Therapeutics Assessment6011
  Assessment by Monotherapy Products601
  Assessment by Target613
  Assessment by Mechanism of Action643
  Assessment by Route of Administration672
  Assessment by Molecule Type692
Drug Profiles71139
  abatacept Drug Profile715
  AbGn-168H Drug Profile762
  ABT-122 Drug Profile782
  adalimumab biosimilar Drug Profile802
  adalimumab biosimilar Drug Profile821
  adalimumab biosimilar Drug Profile831
  adalimumab biosimilar Drug Profile841
  adalimumab biosimilar Drug Profile851
  adalimumab biosimilar Drug Profile861
  adalimumab biosimilar Drug Profile872
  adalimumab biosimilar Drug Profile892
  adalimumab biosimilar Drug Profile911
  adalimumab biosimilar Drug Profile921
  adalimumab biosimilar Drug Profile931
  adalimumab biosimilar Drug Profile941
  adalimumab biosimilar Drug Profile951
  adalimumab biosimilar Drug Profile961
  apremilast Drug Profile9711
  apremilast Drug Profile1081
  bimekizumab Drug Profile1092
  certolizumab pegol biosimilar Drug Profile1111
  clazakizumab Drug Profile1124
  dalazatide Drug Profile1165
  dimethyl fumarate Drug Profile1212
  DNX-114 Drug Profile1231
  DNX-514 Drug Profile1241
  Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Drug Profile1251
  etanercept Drug Profile1262
  etanercept biosimilar Drug Profile1281
  etanercept biosimilar Drug Profile1291
  etanercept biosimilar Drug Profile1301
  etanercept biosimilar Drug Profile1311
  etanercept biosimilar Drug Profile1323
  etanercept biosimilar Drug Profile1351
  etanercept biosimilar Drug Profile1362
  golimumab Drug Profile1388
  golimumab biosimilar Drug Profile1461
  golimumab biosimilar Drug Profile1471
  guselkumab Drug Profile1484
  infliximab biosimilar Drug Profile1521
  infliximab biosimilar Drug Profile1531
  infliximab biosimilar Drug Profile1543
  infliximab biosimilar Drug Profile1571
  infliximab biosimilar Drug Profile1583
  infliximab biosimilar Drug Profile1611
  infliximab biosimilar Drug Profile1621
  INV-17 Drug Profile1631
  itolizumab Drug Profile1642
  ixekizumab Drug Profile1666
  KANAb-071 Drug Profile1721
  KD-025 Drug Profile1734
  liraglutide Drug Profile1777
  PRX-003 Drug Profile1842
  risankizumab Drug Profile1863
  tofacitinib citrate Drug Profile18913
  upadacitinib tartrate Drug Profile2022
  ustekinumab biosimilar Drug Profile2041
  ustekinumab biosimilar Drug Profile2051
  VALBRO-03 Drug Profile2061
  VTP-43742 Drug Profile2073
Psoriatic Arthritis Dormant Projects2102
Psoriatic Arthritis Discontinued Products2121
Psoriatic Arthritis Product Development Milestones21317
  Featured News &Press Releases2131
    Nov 07, 2016: Amgen To Present Data On Etanercept At ACR/ARHP 2016 Annual Meeting2131
    Nov 07, 2016: Pfizer to Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis2142
    Nov 03, 2016: Janssen To Present Data on Guselkumab (Anti-IL23 mAb) At The 2016 American College Of Rheumatology Meeting2162
    Nov 03, 2016: Lilly Presents Data on ixekizumab at 2016 American College of Rheumatology Annual Meeting2181
    Oct 18, 2016: Catalent To Provide Fill &Finish Services For Commercial Supply Of Samsung Bioepis Biosimilar Therapy2181
    Sep 29, 2016: Prothena Outlines Phase 2 Development Strategy for PRX0032191
    Sep 28, 2016: Oral OTEZLA (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis2202
    Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel2221
    Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency2231
    Jun 14, 2016: SIMPONI (golimumab) shows long-term treatment persistence and improved quality of life in patients with rheumatic diseases2232
    Jun 10, 2016: UCB s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis2251
    Jun 09, 2016: Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases2261
    Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016)2261
    Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology2271
    Jun 07, 2016: Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis2282
Appendix2302
  Methodology2301
  Coverage2301
  Secondary Research2301
  Primary Research2301
  Expert Panel Validation2301
  Contact Us2301
  Disclaimer2311

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Psoriatic Arthritis - Pipeline Review, H2 2016" Nov 16, 2016. Alacra Store. May 18, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Psoriatic-Arthritis-Pipeline-Review-H2-2016-2088-16837>
  
APA:
Global Markets Direct - Market Research. (2016). Psoriatic Arthritis - Pipeline Review, H2 2016 Nov 16, 2016. New York, NY: Alacra Store. Retrieved May 18, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Psoriatic-Arthritis-Pipeline-Review-H2-2016-2088-16837>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.